openPR Logo
Press release

Pompe Disease Pipeline 2024 | Immusoft, Asklepios, Oxyrane, Maze Therapeutics, Amicus Therapeutics, Spark Therapeutics

08-02-2024 12:12 AM CET | Health & Medicine

Press release from: ABNewswire

Pompe Disease Pipeline 2024 | Immusoft, Asklepios, Oxyrane,

DelveInsight's, "Pompe Disease Pipeline Insight 2024" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pompe Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Pompe Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ Pompe Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Pompe Disease Pipeline Report

* July 2024:- Amicus Therapeutics :- This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treatment in enzyme replacement therapy (ERT)-experienced and ERT-naive pediatric subjects with Pompe disease, aged 0 to < 18 years.
* July 2024:- Sanofi - An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naive Pediatric Participants With Infantile-Onset Pompe Disease (IOPD).
* DelveInsight's Pompe Disease pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Pompe Disease treatment.
* The leading Pompe Disease Companies such as Immusoft, Asklepios, Oxyrane, Maze Therapeutics, Amicus Therapeutics, Spark Therapeutics , and others.
* Promising Pompe Disease Therapies such as ATB200, AT2221, GC301, avalglucosidase alfa, SPK-3006, and others.

Stay ahead with the most recent pipeline outlook for Pompe Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pompe Disease Treatment Drugs [https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Pompe Disease Emerging Drugs Profile

* AT-GAA: Amicus Therapeutics

AT-GAA developed by Amicus Therapeutics is an investigational therapy that consists of ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, particularly mannose-6 phosphate (M6P), to enhance uptake, co-administered with AT2221, a pharmacological chaperone. In Feb 2019, the US Food and Drug Administration (FDA) granted Amicus a Breakthrough Therapy Designation to AT-GAA for the treatment of late-onset Pompe disease.

* SPK-3006: Spark Therapeutics

SPK-3006 developed by Spark Therapeutics is an investigational Pompe disease gene therapy for the potential treatment of the rare condition. Pompe disease is an oftentimes fatal lysosomal storage disorder and neuromuscular disease, with systemic, multi-organ manifestations resulting from loss of function mutations in the gene encoding acid alpha-glucosidase (GAA). The initial construct for SPK-3006 was in-licensed from Genethon in 2017, and Spark retains global commercialization rights.

Explore groundbreaking therapies and clinical trials in the Pompe Disease Pipeline. Access DelveInsight's detailed report now! @ New Pompe Disease Drugs [https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Pompe Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Pompe Disease Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Unveil the future of Pompe Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Pompe Disease Market Drivers and Barriers [https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Pompe Disease Pipeline Report

* Coverage- Global
* Pompe Disease Companies- Immusoft, Asklepios, Oxyrane, Maze Therapeutics, Amicus Therapeutics, Spark Therapeutics, and others.
* Pompe Disease Therapies- ATB200, AT2221, GC301, avalglucosidase alfa, SPK-3006, and others.
* Pompe Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Pompe Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Pompe Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Pompe Disease Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Pompe Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Pompe Disease- DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* Cipaglucosidase Alfa: Amicus Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SPK-3006: Spark Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* ACTUS-101: Asklepios Biopharmaceutical
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Pompe Disease Key Companies
* Pompe Disease Key Products
* Pompe Disease- Unmet Needs
* Pompe Disease- Market Drivers and Barriers
* Pompe Disease- Future Perspectives and Conclusion
* Pompe Disease Analyst Views
* Pompe Disease Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pompe-disease-pipeline-2024-immusoft-asklepios-oxyrane-maze-therapeutics-amicus-therapeutics-spark-therapeutics]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pompe Disease Pipeline 2024 | Immusoft, Asklepios, Oxyrane, Maze Therapeutics, Amicus Therapeutics, Spark Therapeutics here

News-ID: 3607841 • Views:

More Releases from ABNewswire

Multiple Sclerosis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Biogen, Immune Response BioPharma, Celgene, Novartis, Sanofi, Actelion, Bayer
Multiple Sclerosis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Tri …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple Sclerosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed
The Debut Album of Soldier'z of the Most High (S.O.T.M.H): The City in the Sky Now Available on All Major Platforms - SalvationMusic.com
The Debut Album of Soldier'z of the Most High (S.O.T.M.H): The City in the Sky N …
From sourthern roots and legendary encounters to a new sound called Salvation Music, Chattanooga's own Freddy Mac delivers his long-awaited debut album. Chattanooga, TN - The wait is over. Freddy Mac 2025 and his band Soldier'z of the Most High (S.O.T.M.H) proudly unveil their long-anticipated debut album, The City in the Sky. This groundbreaking project introduces Salvation Music [http://www.salvationmusic.com], a bold fusion of funk, metal, soul, and classical influences, brought to
Author's Tranquility Press Announces the Heartwarming Release of Lil' Hal's Giant Christmas Box
Author's Tranquility Press Announces the Heartwarming Release of Lil' Hal's Gian …
A Christmas Tale of Wonder, Patience, and Family Love That Shines Beyond the Wrapping Paper Few things capture the spirit of Christmas like the thrill of a child discovering a gift under the tree. In Lil' Hal's Giant Christmas Box [https://www.amazon.com/Lil-Hals-Giant-Christmas-Box/dp/195754662X/ref=monarch_sidesheet_title] by Christy B., readers are invited into a magical holiday morning filled with suspense, laughter, and an unforgettable lesson: sometimes the greatest gifts require patience, faith, and love. This beautifully illustrated
"The Expedia of VoIP": Business Phone System Disrupts Carrier Model with Transpa …
Business owners can now shop multiple providers at once-choosing the right system without sales pressure or hidden fees. Sheridan, Wyoming - Business Phone System, a vendor-neutral platform for business communications, today announced its official launch, offering business owners a smarter way to evaluate and select telecom services. Unlike traditional carriers that push their own packages, Business Phone System enables organizations to compare multiple providers side-by-side, ensuring the right solution is sized

All 5 Releases


More Releases for Pompe

Pompe Disease Market Trends That Will Shape the Next Decade: Insights from Innov …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Pompe Disease Market Size By 2025? The market scale for Pompe disease has seen a consistent growth over the past few years. Its size is expected to increase from the current $1.74 billion in 2024 to about $1.8 billion in 2025, exhibiting a compound annual
Leading Element Driving Change in the Pompe Disease Market in 2025: Rising Preva …
How Are the key drivers contributing to the expansion of the pompe disease market? The surge in the occurrence of Pompe disease, which is also known as glycogen storage disease type II or acid maltase deficiency, is anticipated to contribute significantly to the expansion of the Pompe disease market. This rare genetic condition is marked by an accumulation of glycogen, or a complex sugar molecule, in muscles and different body tissues.
Pompe Disease Therapeutics and Treatment Market Report 2024
"The Business Research Company recently released a comprehensive report on the Global Pompe Disease Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. Ready to Dive into Something Exciting? Get Your Free Exclusive Sample
Pompe Disease Treatment Drugs, Pipeline Insight Report 2024
DelveInsight's, "Pompe Disease Pipeline Insight 2024" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pompe Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Pompe
Gaucher & Pompe Diseases Enzyme Replacement Therapy (ERT) Market - Restoring Bal …
Newark, New Castle, USA: The "Gaucher & Pompe Diseases Enzyme Replacement Therapy (ERT) Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Gaucher & Pompe Diseases Enzyme Replacement
Pompe Disease Therapeutic Market - Increasing prevalence of pompe disease in man …
Pompe Disease Therapeutic Market report is a exploration database spread across colorful runners with multiple tables and numbers in it. The exploration covers a precious source of perceptive information for business strategists. Pompe Disease Therapeutic Industry provides the overview with growth analysis and literal & futuristic cost, profit, demand and force data (as applicable). The exploration judges give an elegant description of the value chain and its distributor analysis. This comprehensive